Loss of FHIT function in lung cancer and preinvasive bronchial lesions
- PMID: 9823304
Loss of FHIT function in lung cancer and preinvasive bronchial lesions
Abstract
We previously cloned and characterized the tumor suppressor gene FHIT (fragile histidine triad) at chromosome 3p14.2 and found that this gene is altered by deletions in human tumors, including lung cancer. To assess the frequency and specificity of inactivation and its relevance in a clinical setting, we have produced antibodies against the Fhit protein and studied its expression in a series of non-small cell lung cancers and normal bronchial mucosa and a spectrum of preinvasive lesions by immunohistochemistry. The data indicate that the loss of Fhit protein is the most frequent alteration in non-small cell lung cancer (73%) and precancerous lesions (93%), is significantly higher in the tumors of smokers (75%) than in those of nonsmokers (39%; P < 0.0005), and is an independent and more frequent event than p53 overexpression in tumors and precancerous lesions (73 versus 46%). The percentage of cases lacking Fhit expression was higher in the squamous type compared to adenocarcinoma (87 versus 57%; P < 0.00001), whereas other histotypes (large cell, mucoepidermal) showed an intermediate value (69%). Loss of Fhit expression in a very high percentage of primary lung carcinomas and precancerous lesions supports the notion that FHIT alterations play an important role in the growth control of bronchial cells. FHIT inactivation is particularly important in squamous cell carcinomas that are often associated with precursor dysplastic lesions. The overall high frequency and precocity of Fhit loss in lung carcinogenesis and the development of the presently described immunohistochemical approach suggest a potential use of this gene in the early detection of lung cancer and in chemopreventive studies as an intermediate biomarker.
Similar articles
-
Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer.Cancer Res. 1998 Jun 15;58(12):2533-6. Cancer Res. 1998. PMID: 9635574
-
Association of allelic loss at the FHIT locus and p53 alterations with tumour kinetics and chromosomal instability in non-small cell lung carcinomas (NSCLCs).J Pathol. 2001 Jan;193(1):55-65. doi: 10.1002/1096-9896(2000)9999:9999<::AID-PATH731>3.0.CO;2-#. J Pathol. 2001. PMID: 11169516
-
Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers.Cancer Res. 1999 Oct 1;59(19):4798-803. Cancer Res. 1999. PMID: 10519387
-
FHITness and cancer.Oncol Res. 1998;10(7):341-5. Oncol Res. 1998. PMID: 10063967 Review.
-
The Fragile Histidine Triad gene and breast cancer.Med Sci Monit. 2002 Jul;8(7):RA140-4. Med Sci Monit. 2002. PMID: 12118213 Review.
Cited by
-
Fhit expression in human gastric adenomas and intramucosal carcinomas: correlation with Mlh1 expression and gastric phenotype.Br J Cancer. 2004 Feb 9;90(3):672-7. doi: 10.1038/sj.bjc.6601601. Br J Cancer. 2004. PMID: 14760383 Free PMC article.
-
Fhit loss in lung preneoplasia: relation to DNA damage response checkpoint activation.Cancer Lett. 2010 May 28;291(2):230-6. doi: 10.1016/j.canlet.2009.10.017. Cancer Lett. 2010. PMID: 19931269 Free PMC article.
-
Pulmonary preinvasive neoplasia.J Clin Pathol. 2001 Apr;54(4):257-71. doi: 10.1136/jcp.54.4.257. J Clin Pathol. 2001. PMID: 11304841 Free PMC article. Review.
-
The FHIT gene product: tumor suppressor and genome "caretaker".Cell Mol Life Sci. 2014 Dec;71(23):4577-87. doi: 10.1007/s00018-014-1722-0. Epub 2014 Oct 5. Cell Mol Life Sci. 2014. PMID: 25283145 Free PMC article. Review.
-
Human papillomavirus and lung cancinogenesis: an overview.J Cancer Res Clin Oncol. 2016 Dec;142(12):2415-2427. doi: 10.1007/s00432-016-2197-1. Epub 2016 Jun 29. J Cancer Res Clin Oncol. 2016. PMID: 27357515 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous